Cargando…
CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3
BACKGROUND: Platinum-based chemotherapy is emerging as the first line of treatment for castration resistant prostate cancer. Among the family of platinum (IV)-based compounds, a member known as CPA-7 inhibits the growth of multiple cancer cell lines. However, how and to what extent CPA-7 elicits its...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4952363/ https://www.ncbi.nlm.nih.gov/pubmed/27435207 http://dx.doi.org/10.1186/s12885-016-2488-6 |